Sueangoen N.Thuwajit P.Yenchitsomanus P.T.Thuwajit C.Mahidol University2024-06-252024-06-252024-07-01International Journal of Molecular Medicine Vol.54 No.1 (2024)11073756https://repository.li.mahidol.ac.th/handle/20.500.14594/99015Among women globally, breast cancer is the most prevalent cancer and the leading cause of cancer‑related death. Interestingly, though genetic mutations contribute to the disease, <15% of women diagnosed with breast cancer have a family history of the disease, suggesting a prevalence of sporadic genetic mutations in breast cancer development. In the rapidly rising field of cancer genomics, neoantigen‑based immunotherapy has come to the fore. The investigation of novel proteins arising from unique somatic mutations or neoantigens have opened a new pathway for both individualized and public cancer treatments. Because they are shared among individuals with similar genetic changes, public neoantigens provide an opportunity for ‘off‑the‑shelf’ anticancer therapies, potentially extending the benefits to a wider patient group. The present review aimed to highlight the role of shared or public neoan‑ tigens as therapeutic targets for patients with breast cancer, emphasizing common hotspot mutations of certain genes identified in breast cancer. The clinical utilization of public neoantigen‑based therapies for breast cancer treatment were also discussed.Biochemistry, Genetics and Molecular BiologyReviewSCOPUS10.3892/ijmm.2024.53882-s2.0-851964092581791244X